GEXVal Receives Formal PMDA Opinion Letter for Lead Program GXV-001
2026/3/24
GEXVal Inc.March 24, 2026 GEXVal Receives Formal PMDA Opinion Letter for Lead Program GXV-001-Post-Operative D […]
CTO Nakayama Contributes Invited Article to Experimental Medicine, Japan’s Leading Life Science Journal, on AI-Driven Drug Discovery
2026/3/12
GEXVal Inc.March 12, 2026 CTO Nakayama Contributes Invited Article to Experimental Medicine Special Issue on A […]
World Rare Disease Day: GEXVal Presents Posters at 5th Tsukuba Co-creation Conference
2026/3/3
GEXVal Inc.March 3, 2026 World Rare Disease Day: GEXVal Presents Two Posters at 5th Tsukuba Co-creation Confer […]
Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation
2026/2/28
GEXVal Inc.February 28, 2026 FRAXA Research Foundation Features GEXVal's Completion of FRAXA-DVI Program and F […]
GEXVal Selected as Presenting Company at Biotech Showcase™ 2026
2026/1/7
GEXVal Inc.January 7, 2026 GEXVal Selected as Presenting Company at Biotech Showcase™ 2026 GEXVal Inc. (Presid […]